Search Within

Hematology-Oncology Fellows

Formats
  1. Meeting Abstract (2134)
  2. Journal Article (1755)
  3. Review (262)
  4. Editorial (133)
  5. Research Letter (85)
  6. Correspondence (45)
  7. Book Section (31)
  8. Guidelines (25)
  9. Miscellaneous (13)
  10. Conference Paper (8)
Groups
  1. Department of Medicine (4172)
  2. Weinberg Fellows (2756)
  3. Hematologic Malignancies, Division of (2492)
  4. Solid Tumor Oncology Division (2422)
  5. Center for Hematologic Malignancies (1945)
  6. GSK Faculty (1879)

More Groups

People
  1. Sergio Giralt (433)
  2. Michael Scordo (389)
  3. Gunjan Shah (348)
  4. Miguel-Angel Perales (338)
  5. Sean Devlin (289)
  6. Marcel Van Den Brink (263)

More People

Years
  1. 2025 (343)
  2. 2024 (636)
  3. 2023 (600)
  4. 2022 (628)
  5. 2021 (503)
  6. 2020 (496)

More Years

Publications
  1. Blood (713)
  2. Journal of Clinical Oncology (685)
  3. Annals of Oncology (133)
  4. Clinical Cancer Research (131)
  5. Cancer Research (126)
  6. Biology of Blood and Marrow Transplantation (124)

More Publications

Publishers
  1. American Society of Hematology (806)
  2. American Society of Clinical Oncology (774)
  3. Elsevier Inc. (544)
  4. Nature Publishing Group (358)
  5. American Association for Cancer Research (352)
  6. Oxford University Press (211)

More Publishers

Results (4491)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Murray, J. C.; Huang, Q.; Hu, C.; Curran, E.; Wong, C.; Glatz, L.; Wang, T.; Hasan, A.; Villaruz, L.; Schoenfeld, A.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
    Meeting Abstract

    Di Federico, A.; Chen, M. F.; Pagliaro, A.; Ogliari, F. R.; Stockhammer, P.; Aldea, M.; Grant, M.; De Giglio, A.; Alessi, J. V.; Pecci, F.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
    Meeting Abstract

    Betof Warner, A.; Smithy, J. W.; Los, C.; Kalvin, H.; Hasson, N.; Amaria, R. N.; Andrade Czapla, J. A.; Schollenberger, M.; furness, A.; Hassel, J. C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • NivoLag-when: International real-world study of combination immunotherapy sequences in melanoma
    Meeting Abstract

    Guardamagna, M.; Marqueste, C. G.; Malissen, N.; Roy, S.; da Silva, I. P.; Long, G. V.; Smithy, J. W.; Postow, M. A.; Dimitriou, F.; Dummer, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors
    Meeting Abstract

    Sanborn, R. E.; Patel, M. R.; Rodon, J.; Thein, K. Z.; Friedman, C.; Levitz, D.; Ngirailemesang, I.; Goodman, A.; Agarwal, P.; Friedman, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Dunn, L.; Cracchiolo, J.; Ho, A. L.; Sherman, E. J.; Ganly, I.; Ghossein, R.; Cohen, M.; Wong, W.; Desilets, A.; Michel, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors
    Meeting Abstract

    Ray-Coquard, I. L.; Liu, J. F.; O'Malley, D.; Oaknin, A.; Pothuri, B.; Lorusso, D.; Eskander, R. N.; Westin, S.; Lakhani, N. J.; McKean, W. B.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)
    Meeting Abstract

    Friedman, C.; De Burgh Williams, A.; Lopez, J. S.; Ouali, K.; Middleton, M. R.; Thistlethwaite, F.; Hamid, O.; Izar, B.; Moreno Garcia, V.; Johnson, M. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
    Meeting Abstract

    Schram, A. M.; Lopes, G.; El-Khoueiry, A. B.; Fontana, E.; Karasic, T. B.; Kummar, S.; Lorusso, P.; Gregorc, V.; Millward, M.; Aix, S. P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors
    Meeting Abstract

    Powles, T. B.; Bhatia, A. K.; Burtness, B.; Kogawa, T.; Nishina, T.; Nakayama, I.; Fountzilas, C.; Castillo, D. R.; McKean, M.; Meric-Bernstam, F.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save